Abstract:Purpose/Objective(s)Transforming growth factor-β1 (TGF-β1) is a candidate for the pathogenesis of radiation-induced pneumonitis (RP). We attempted to elucidate the association between TGF-β1 genetic variations and risk of RP among Chinese patients with non-small-cell lung cancer (NSCLC).Materials/MethodsBetween 2004 and 2007, 179 Chinese NSCLC patients receiving definitive thoracic irradiation were recruited. The Common Terminology Criteria for Adverse Events v3.0 was used to grade RP. Three variants of TGF-β1 gene, C-509T (rs1800469), T869C (rs1800470), and G915C (rs1800471) were genotyped using polymerase chain reaction-restriction fragment length polymorphism method or direct PCR sequencing. Plasma TGF-β1 level was measured using an enzyme-linked immunosorbent assay. Cox regression analysis was used to determine factors associated with RP risk. Mann-Whitney U test was used for skewed variables such as circulating TGF-β1 levels.ResultsAmong all the patients, 145 were male and 34 were female. The median age was 61 years. Forty-nine patients received RT alone, and 130 received combined platinum-based chemoradiotherapy. After a median follow-up of 22 months, 28 patients (15.6%) developed ≥grade 2 RP. In our Chinese patients, the frequencies of CC genotype in C-509T, GG in G915C, or TT in T869C were 25.9%,100%, and 29.8%, respectively, which were significant different from those observed in Whites, with the incidences of 61.3% (p < 0.001), 87.9% (p < 0.001), and 31.9% (p = 0.009), respectively. No significant associations were found among the genotypes and RP risk for C-509T and T869C SNPs (p = 0.81 and p = 0.84, respectively). The mean pre-RT TGF-β1 level was 4.06 ± 0.46ng/mL, and the mean during-RT TGF-β1 level was 3.71 ± 0.44ng/mL. No significant differences in pre-RT TGF-β1 levels for C-509T and T869C SNPs were observed between different genotypes (p = 0.95 and p = 0.83, respectively). The same analyses were performed for during-RT TGF-β1 levels, and the results were the same (p = 0.99 and p = 0.47, respectively).ConclusionsThe genotype distributions of the three TGF-β1 variants are significantly dependent on ethnicity. Different from previous reports involving Whites, polymorphisms of the TGF-β1 gene do not represent a genetic predisposition to RP susceptibility in Chinese. In addition, neither of the two frequent polymorphisms in Chinese (C-509T and T869C), have been found to be associated with the circulating level of the TGF-β1 gene product. Purpose/Objective(s)Transforming growth factor-β1 (TGF-β1) is a candidate for the pathogenesis of radiation-induced pneumonitis (RP). We attempted to elucidate the association between TGF-β1 genetic variations and risk of RP among Chinese patients with non-small-cell lung cancer (NSCLC). Transforming growth factor-β1 (TGF-β1) is a candidate for the pathogenesis of radiation-induced pneumonitis (RP). We attempted to elucidate the association between TGF-β1 genetic variations and risk of RP among Chinese patients with non-small-cell lung cancer (NSCLC). Materials/MethodsBetween 2004 and 2007, 179 Chinese NSCLC patients receiving definitive thoracic irradiation were recruited. The Common Terminology Criteria for Adverse Events v3.0 was used to grade RP. Three variants of TGF-β1 gene, C-509T (rs1800469), T869C (rs1800470), and G915C (rs1800471) were genotyped using polymerase chain reaction-restriction fragment length polymorphism method or direct PCR sequencing. Plasma TGF-β1 level was measured using an enzyme-linked immunosorbent assay. Cox regression analysis was used to determine factors associated with RP risk. Mann-Whitney U test was used for skewed variables such as circulating TGF-β1 levels. Between 2004 and 2007, 179 Chinese NSCLC patients receiving definitive thoracic irradiation were recruited. The Common Terminology Criteria for Adverse Events v3.0 was used to grade RP. Three variants of TGF-β1 gene, C-509T (rs1800469), T869C (rs1800470), and G915C (rs1800471) were genotyped using polymerase chain reaction-restriction fragment length polymorphism method or direct PCR sequencing. Plasma TGF-β1 level was measured using an enzyme-linked immunosorbent assay. Cox regression analysis was used to determine factors associated with RP risk. Mann-Whitney U test was used for skewed variables such as circulating TGF-β1 levels. ResultsAmong all the patients, 145 were male and 34 were female. The median age was 61 years. Forty-nine patients received RT alone, and 130 received combined platinum-based chemoradiotherapy. After a median follow-up of 22 months, 28 patients (15.6%) developed ≥grade 2 RP. In our Chinese patients, the frequencies of CC genotype in C-509T, GG in G915C, or TT in T869C were 25.9%,100%, and 29.8%, respectively, which were significant different from those observed in Whites, with the incidences of 61.3% (p < 0.001), 87.9% (p < 0.001), and 31.9% (p = 0.009), respectively. No significant associations were found among the genotypes and RP risk for C-509T and T869C SNPs (p = 0.81 and p = 0.84, respectively). The mean pre-RT TGF-β1 level was 4.06 ± 0.46ng/mL, and the mean during-RT TGF-β1 level was 3.71 ± 0.44ng/mL. No significant differences in pre-RT TGF-β1 levels for C-509T and T869C SNPs were observed between different genotypes (p = 0.95 and p = 0.83, respectively). The same analyses were performed for during-RT TGF-β1 levels, and the results were the same (p = 0.99 and p = 0.47, respectively). Among all the patients, 145 were male and 34 were female. The median age was 61 years. Forty-nine patients received RT alone, and 130 received combined platinum-based chemoradiotherapy. After a median follow-up of 22 months, 28 patients (15.6%) developed ≥grade 2 RP. In our Chinese patients, the frequencies of CC genotype in C-509T, GG in G915C, or TT in T869C were 25.9%,100%, and 29.8%, respectively, which were significant different from those observed in Whites, with the incidences of 61.3% (p < 0.001), 87.9% (p < 0.001), and 31.9% (p = 0.009), respectively. No significant associations were found among the genotypes and RP risk for C-509T and T869C SNPs (p = 0.81 and p = 0.84, respectively). The mean pre-RT TGF-β1 level was 4.06 ± 0.46ng/mL, and the mean during-RT TGF-β1 level was 3.71 ± 0.44ng/mL. No significant differences in pre-RT TGF-β1 levels for C-509T and T869C SNPs were observed between different genotypes (p = 0.95 and p = 0.83, respectively). The same analyses were performed for during-RT TGF-β1 levels, and the results were the same (p = 0.99 and p = 0.47, respectively). ConclusionsThe genotype distributions of the three TGF-β1 variants are significantly dependent on ethnicity. Different from previous reports involving Whites, polymorphisms of the TGF-β1 gene do not represent a genetic predisposition to RP susceptibility in Chinese. In addition, neither of the two frequent polymorphisms in Chinese (C-509T and T869C), have been found to be associated with the circulating level of the TGF-β1 gene product. The genotype distributions of the three TGF-β1 variants are significantly dependent on ethnicity. Different from previous reports involving Whites, polymorphisms of the TGF-β1 gene do not represent a genetic predisposition to RP susceptibility in Chinese. In addition, neither of the two frequent polymorphisms in Chinese (C-509T and T869C), have been found to be associated with the circulating level of the TGF-β1 gene product.

Abstract:Purpose/Objective(s)To investigate the association between single nucleotide polymorphisms (SNPs) in TGF-β1 gene and risks of treatment related pneumonitis (TRP), overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) in patients with NSCLC.Materials/MethodsUsing 217 available genomic DNA samples from NSCLC patients treated with definitive radiotherapy at our institution between 11/1998 and 1/2005, we genotyped three SNPs of the TGF-β1 gene (rs1800469:C-509T, rs1800471:G915C, and rs1982073:T869C) by polymerase chain reaction-restriction fragment length polymorphism method. We used Kaplan-Meier cumulative probability to assess the risk of Grade ≥1 TRP, OS, PFS, and DMFS. Cox proportional hazards analyses to evaluate the effect of TGF-β1 genotypes on such risk.ResultsThere were 124 men and 93 women in the study, with median age of 63 years. The median total radiation dose was 63 Gy (range, 50.4– 84.0 Gy) given in 1.8- to 2-Gy fractions once a day (151 patients) or in 1.2 Gy fractions twice a day (66 patients); 97% of patients received 60–70 Gy. The median follow-up times was 17 and 39 months for the entire group and living patients (range, 1–97 months), respectively. Grades ≥1, ≥2, and ≥ 3 TRP were observed in 151(69.5%), 88 (40.5%) and 40 patients (18.4%), respectively. Multivariate analysis found CT genotypes of TGF-β1 rs1982073:T869C to be associated with a statistically significantly lower risk of TRP Grades ≥ 1 (hazard ratio [HR] = 0.668; 95% CI, 0.475 to 0.957; p = .037) compared with the TT genotype. The median times of OS, PFS, and DMFS were 17, 8, and 10 months, respectively. Multivariate analysis showed that having the CT genotype in TGFβ1 rs1982073 predicted poor PFS (HR = 1.603, 95% confidence interval [CI] = 1.117–2.301, p = 0.01) and DMFS (HR = 1.823, 95% CI = 1.157–2.874, p = 0.01) in all patients and in those with brain metastases (HR = 3.491, 95% CI =1.525–7.989, p = 0.003). Having the CT genotype in TGFβ1 rs1800469 was also associated with shorter DMFS (HR = 1.569, 95% CI = 1.040–2.367, p = 0.032). OS was not associated with genotype at any of the three SNPs assessed. All HRs were adjusted for age, gender, race, Karnofsky performance score (KPS), smoking status, tumor histology, gross tumor volume(GTV), disease stage, concurrent chemoradiation therapy, and radiation dose received.ConclusionsOur finding suggests that TGF-β1 SNP rs1982073:T869C may be an important predictive biomarker for risk of toxicity and distant metastasis before treatment initiation, therefore used in selecting patients for personalization of treatments for NSCLC. Larger studies are needed for validation. Purpose/Objective(s)To investigate the association between single nucleotide polymorphisms (SNPs) in TGF-β1 gene and risks of treatment related pneumonitis (TRP), overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) in patients with NSCLC. To investigate the association between single nucleotide polymorphisms (SNPs) in TGF-β1 gene and risks of treatment related pneumonitis (TRP), overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) in patients with NSCLC. Materials/MethodsUsing 217 available genomic DNA samples from NSCLC patients treated with definitive radiotherapy at our institution between 11/1998 and 1/2005, we genotyped three SNPs of the TGF-β1 gene (rs1800469:C-509T, rs1800471:G915C, and rs1982073:T869C) by polymerase chain reaction-restriction fragment length polymorphism method. We used Kaplan-Meier cumulative probability to assess the risk of Grade ≥1 TRP, OS, PFS, and DMFS. Cox proportional hazards analyses to evaluate the effect of TGF-β1 genotypes on such risk. Using 217 available genomic DNA samples from NSCLC patients treated with definitive radiotherapy at our institution between 11/1998 and 1/2005, we genotyped three SNPs of the TGF-β1 gene (rs1800469:C-509T, rs1800471:G915C, and rs1982073:T869C) by polymerase chain reaction-restriction fragment length polymorphism method. We used Kaplan-Meier cumulative probability to assess the risk of Grade ≥1 TRP, OS, PFS, and DMFS. Cox proportional hazards analyses to evaluate the effect of TGF-β1 genotypes on such risk. ResultsThere were 124 men and 93 women in the study, with median age of 63 years. The median total radiation dose was 63 Gy (range, 50.4– 84.0 Gy) given in 1.8- to 2-Gy fractions once a day (151 patients) or in 1.2 Gy fractions twice a day (66 patients); 97% of patients received 60–70 Gy. The median follow-up times was 17 and 39 months for the entire group and living patients (range, 1–97 months), respectively. Grades ≥1, ≥2, and ≥ 3 TRP were observed in 151(69.5%), 88 (40.5%) and 40 patients (18.4%), respectively. Multivariate analysis found CT genotypes of TGF-β1 rs1982073:T869C to be associated with a statistically significantly lower risk of TRP Grades ≥ 1 (hazard ratio [HR] = 0.668; 95% CI, 0.475 to 0.957; p = .037) compared with the TT genotype. The median times of OS, PFS, and DMFS were 17, 8, and 10 months, respectively. Multivariate analysis showed that having the CT genotype in TGFβ1 rs1982073 predicted poor PFS (HR = 1.603, 95% confidence interval [CI] = 1.117–2.301, p = 0.01) and DMFS (HR = 1.823, 95% CI = 1.157–2.874, p = 0.01) in all patients and in those with brain metastases (HR = 3.491, 95% CI =1.525–7.989, p = 0.003). Having the CT genotype in TGFβ1 rs1800469 was also associated with shorter DMFS (HR = 1.569, 95% CI = 1.040–2.367, p = 0.032). OS was not associated with genotype at any of the three SNPs assessed. All HRs were adjusted for age, gender, race, Karnofsky performance score (KPS), smoking status, tumor histology, gross tumor volume(GTV), disease stage, concurrent chemoradiation therapy, and radiation dose received. There were 124 men and 93 women in the study, with median age of 63 years. The median total radiation dose was 63 Gy (range, 50.4– 84.0 Gy) given in 1.8- to 2-Gy fractions once a day (151 patients) or in 1.2 Gy fractions twice a day (66 patients); 97% of patients received 60–70 Gy. The median follow-up times was 17 and 39 months for the entire group and living patients (range, 1–97 months), respectively. Grades ≥1, ≥2, and ≥ 3 TRP were observed in 151(69.5%), 88 (40.5%) and 40 patients (18.4%), respectively. Multivariate analysis found CT genotypes of TGF-β1 rs1982073:T869C to be associated with a statistically significantly lower risk of TRP Grades ≥ 1 (hazard ratio [HR] = 0.668; 95% CI, 0.475 to 0.957; p = .037) compared with the TT genotype. The median times of OS, PFS, and DMFS were 17, 8, and 10 months, respectively. Multivariate analysis showed that having the CT genotype in TGFβ1 rs1982073 predicted poor PFS (HR = 1.603, 95% confidence interval [CI] = 1.117–2.301, p = 0.01) and DMFS (HR = 1.823, 95% CI = 1.157–2.874, p = 0.01) in all patients and in those with brain metastases (HR = 3.491, 95% CI =1.525–7.989, p = 0.003). Having the CT genotype in TGFβ1 rs1800469 was also associated with shorter DMFS (HR = 1.569, 95% CI = 1.040–2.367, p = 0.032). OS was not associated with genotype at any of the three SNPs assessed. All HRs were adjusted for age, gender, race, Karnofsky performance score (KPS), smoking status, tumor histology, gross tumor volume(GTV), disease stage, concurrent chemoradiation therapy, and radiation dose received. ConclusionsOur finding suggests that TGF-β1 SNP rs1982073:T869C may be an important predictive biomarker for risk of toxicity and distant metastasis before treatment initiation, therefore used in selecting patients for personalization of treatments for NSCLC. Larger studies are needed for validation. Our finding suggests that TGF-β1 SNP rs1982073:T869C may be an important predictive biomarker for risk of toxicity and distant metastasis before treatment initiation, therefore used in selecting patients for personalization of treatments for NSCLC. Larger studies are needed for validation.

A Study of Ethnic Differences in TGFβ1 Gene Polymorphisms and Effects on the Risk of Radiation Pneumonitis in Non–Small-Cell Lung Cancer

TGFβ1 Gene Polymorphisms with the Risk of Radiation Pneumonitis in Non-Small Cell Lung Cancer in Different Ethnic Study.

TGF-β1 Gene Polymorphisms Are Not Associated with Risk of Radiation-induced Pneumonitis in Chinese

Genetic polymorphisms of transforming growth factor-β1 and its receptors and colorectal cancer susceptibility: A population-based case-control study in China

TGF‐β1 rs1982073 polymorphism contributes to radiation pneumonitis in lung cancer patients: a meta‐analysis

Single Nucleotide Polymorphism of the TGF-B1 T869C Gene Associates Risks of Treatment Related Pneumonitis and Distant Metastasis in Patients with Non–small-cell Lung Cancer Treated with Definitive Radiotherapy

Functional Promoter Rs2868371 Variant of Hspb1 Associates with the Risk of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Treated with Radiotherapy

Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes after Definitive Radiotherapy for Non-Small-Cell Lung Cancer.

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Abstract 4582: Genome-wide Association Study of Toxicity Following Definitive Radiotherapy in Non-Small Cell Lung Cancer Patients.

Genetic Variations in the Transforming Growth Factor-β1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer

Tgfbr1 Haplotypes and Risk of Non-Small-Cell Lung Cancer

Association of DNA repair gene polymorphisms with the risk of radiation pneumonitis in lung cancer patients.

Prognostic Value of Transforming Growth Factor Beta Receptor 1 Polymorphisms in Patients with Oral Cancer.

Polymorphisms of BMP4 and HIF-1A Are Associated with Patient-Reported Symptoms in Non-Small-Cell Lung Cancer Patients Treated with Definitive Chemoradiation Therapy

HSPB1 Gene Polymorphisms Predict Risk of Mortality for US Patients after Radio(chemo)therapy for Non-Small Cell Lung Cancer

Abstract 3626: Inflammation-related Genetic Variants Predict Radiation-Induced Toxicity Following Definitive Radiotherapy for Non-Small Cell Lung Cancer.

No Association Between TGFB1 Polymorphisms and Late Radiotherapy Toxicity: A Meta-Analysis

Association between TGF-β1 rs1982073/rs1800469 polymorphism and lung cancer susceptibility: An updated meta-analysis involving 7698 cases and controls.

Genetic Variants In Inflammation-Related Genes Are Associated With Radiation-Induced Toxicity Following Treatment For Non-Small Cell Lung Cancer

RAD18 Polymorphisms Are Associated with Platinum-Based Chemotherapy Toxicity in Chinese Patients with Non-Small Cell Lung Cancer